Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28422929 | 0.97 | FDPS (0.34) | FDPSTSHRLMNATHRBGGPS1 | |
| SCHEMBL525489 | 0.92 | GGPS1 (0.41) | FDPSTSHRTHRBGGPS1 | |
| SCHEMBL3372046 | 0.89 | GGPS1 (0.43) | FDPSTSHRTHRBGGPS1 | |
| SCHEMBL4597693 | 0.89 | GGPS1 (0.43) | FDPSTSHRTHRBGGPS1 | |
| SCHEMBL7582387 | 0.89 | GGPS1 (0.43) | FDPSTSHRTHRBGGPS1 | |
| SCHEMBL5028617 | 0.89 | FDPS (0.33) | FDPSTSHRLMNA | |
| SCHEMBL16290253 | 0.84 | TSHR (0.46) | TSHR | |
| SCHEMBL11193899 | 0.81 | FDPS (0.32) | FDPS | |
| SCHEMBL8654583 | 0.79 | GGPS1 (0.40) | FDPSTSHRTHRBGGPS1 | |
| SCHEMBL10477271 | 0.79 | GGPS1 (0.40) | FDPSTSHRTHRBGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3818099-A1 | HIGH PLA CONTENT PLASTIC MATERIAL COMPRISING A CITRATE ESTER | Carbiolice (FR) | 2021-05-12 | — | — | EP | claimed |
| WO-2020008029-A1 | HIGH PLA CONTENT PLASTIC MATERIAL COMPRISING A CITRATE ESTER | CARBIOLICE (FR) | 2020-01-09 | — | — | WO | claimed |
| EP-2363117-B1 | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids | APTALIS PHARMATECH INC (US) | 2015-08-19 | — | — | EP | claimed |
| EP-2748275-A1 | METHODS OF FLUID LOSS CONTROL, DIVERSION, AND SEALING USING DEFORMABLE PARTICULATES | Halliburton Energy Services, Inc. (US) | 2014-07-02 | — | — | EP | claimed |
| US-20130224170-A1 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2013-08-29 | — | — | US | claimed |
| US-20130108605-A1 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2013-05-02 | — | — | US | claimed |
| WO-2013052252-A1 | METHODS OF FLUID LOSS CONTROL, DIVERSION, AND SEALING USING DEFORMABLE PARTICULATES | HALLIBURTON ENERGY SERVICES, INC. (US) | 2013-04-11 | — | — | WO | claimed |
| US-20110237525-A1 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET | EMERAMED LIMITED (IE) | 2011-09-29 | — | — | US | claimed |
| US-7005460-B2 | Two-step curable mixer-suitable materials | KETTENBACH GMBH & CO. KG (DE) | 2006-02-28 | — | — | US | claimed |
| EP-4364743-A2 | A MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS | Empros Pharma AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| US-11975105-B2 | Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders | EMPROS PHARMA AB (SE) | 2024-05-07 | — | — | US | disclosed |
| US-11927585-B2 | Solvent-based inks and coatings for food contact applications | SUN CHEMICAL CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4259434-A1 | CERAMIC MIXTURE FOR PRODUCING MOULDED ARTICLES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF | Pritidenta GmbH (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-20230243805-A1 | SOLVENT-BASED INKS AND COATINGS FOR FOOD CONTACT APPLICATIONS | SUN CHEMICAL CORPORATION (US) | 2023-08-03 | — | — | US | disclosed |
| US-4789700-A | PVC PLASTICIZERS; HEAT RESISTANCE, NONTOXIC | MORFLEX CHEMICAL COMPANY, INC. (US) | 1988-12-06 | — | — | US | disclosed |
| US-4711922-A | PLASTICIZERS FOR POLYVINYL CHLORIDE MEDICAL EQUIPMENT; HEAT RESISTANCE | MORFLEX CHEMICAL COMPANY, INC. (US) | 1987-12-08 | — | — | US | disclosed |
| US-4710532-A | POLYVINYL CHLORIDE WITH CITRATE ESTER PLASTICIZER; NONTOXIC | MORFLEX CHEMICAL COMPANY, INC. (US) | 1987-12-01 | — | — | US | disclosed |
| US-4600577-A | HYPOTENS&VE AGENTS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELKAB) (DK) | 1986-07-15 | — | — | US | disclosed |
| US-4502482-A | Endotracheal tube complex | DELUCCIA VICTOR C | 1985-03-05 | — | — | US | disclosed |
| US-4422877-A | VAPORIZATION WITH NONSOLVENT WHICH IS SOLUBLE WITH PROPELLANT BUT NOT SOLUBLE WITH POLYMER | RESTECH RESEARCH LIMITED PARTNERSHIP (US) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224170-A1 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET | TXNRD2, GPX4, GSR | FDPS 3042/4885TSHR 1507/4885LMNA 3253/4885 |
| US-20110237525-A1 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET | TXNRD2, GPX4, GSR | FDPS 3042/4885TSHR 1507/4885LMNA 3253/4885 |
| US-11975105-B2 | Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders | LIPC, ACAT2, ACACB | FDPS 3145/4885TSHR 1663/4885LMNA 3335/4885 |
| US-20130108605-A1 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET | TXNRD2, GPX4, GSR | FDPS 3042/4885TSHR 1507/4885LMNA 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.